Provided by Tiger Trade Technology Pte. Ltd.

Enanta Pharmaceuticals

12.18
-0.3300-2.64%
Post-market: 12.180.00000.00%16:10 EDT
Volume:121.46K
Turnover:1.48M
Market Cap:353.45M
PE:-3.95
High:13.28
Open:12.41
Low:11.97
Close:12.51
52wk High:17.15
52wk Low:4.09
Shares:29.02M
Float Shares:20.83M
Volume Ratio:0.83
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0871
EPS(LYR):-3.8381
ROE:-60.01%
ROA:-13.47%
PB:2.79
PE(LYR):-3.17

Loading ...

Enanta Pharmaceuticals veröffentlicht Jahresbericht für 2025

Reuters
·
Feb 06

Enanta Pharmaceuticals Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Reuters
·
Jan 27

Enanta Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 09

Enanta Pharmaceuticals (ENTA) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Jan 09

Enanta Pharmaceuticals Files Patent Infringement Lawsuit Against Pfizer Over Paxlovid in EU Unified Patent Court

Reuters
·
Jan 08

Enanta Pharmaceuticals Inc - Continuing Phase 3 Activities With FDA for Zelicapavir

THOMSON REUTERS
·
Jan 08

Enanta Pharmaceuticals Provides Update on Its Research and Development Programs and 2026 Outlook

THOMSON REUTERS
·
Jan 08

Have Insiders Sold Enanta Pharmaceuticals Shares Recently?

Simply Wall St.
·
Dec 08, 2025

Enanta Pharmaceuticals CEO Jay R. Luly Reports Sale of Common Shares

Reuters
·
Dec 06, 2025

Enanta Pharmaceuticals Officer Harry R. Trout III Reports Disposal of Common Shares

Reuters
·
Dec 04, 2025

Enanta Pharmaceuticals Inc : Leerink Partners Raises Target Price to $11 From $9

THOMSON REUTERS
·
Nov 20, 2025

Enanta Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating

TIPRANKS
·
Nov 19, 2025

Enanta Pharmaceuticals Reports Progress in Drug Development

TIPRANKS
·
Nov 18, 2025

Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise

Dow Jones
·
Nov 18, 2025

Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET

Reuters
·
Nov 18, 2025

Enanta reports Q4 EPS (87c), consensus ($1.01)

TIPRANKS
·
Nov 18, 2025

Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025

Reuters
·
Nov 18, 2025

Enanta Pharma Q4 EPS $(0.87) Beats $(1.03) Estimate, Sales $15.125M Miss $15.956M Estimate

Benzinga
·
Nov 18, 2025

BRIEF-Enanta Pharmaceuticals Q4 Revenue USD 15.125 Million

Reuters
·
Nov 18, 2025

Enanta Sues Pfizer in EU Over Paxlovid Patent Infringement

Reuters
·
Nov 18, 2025